ADVERTISEMENT

Newly Available, Newly Approved

The American Journal of Orthopedics. 2007 October;36(10):566
Author and Disclosure Information

HIP-BEARING SYSTEM

DePuy Orthopaedics, Inc., has announced a new option for restoring hip mobility in patients who require total hip replacement: the Pinnacle® Acetabular Cup System AltrX™ hip bearing. This system provides advanced technology for recreating the natural ball-and-socket joint of the hip to help increase joint stability, range of motion, and longevity.1, 2

The AltrX polyethylene bearing is used with DePuy’s Pinnacle Acetabular Cup System — the only product available that provides surgeons with the option of choosing a polyethylene or metal insert for use with the same outer titanium cup that replaces the socket of the natural hip.

The Pinnacle cup exhibited 99% survivorship at 5 years and differences between patients, surgeons, femoral stems, head size, and articulation types did not affect survival.3

Key benefits are said to include significant wear reduction, with AltrX polyethylene liners achieving a 92% wear reduction over conventional polyethylene liners, while maintaining excellent mechanical integrity and oxidative resistance in laboratory simulations.4 In addition, the system is designed to provide optimized mechanical integrity by using an AltraLink™ material enhancement process. DePuy notes that AltrX liners achieve excellent mechanical toughness and oxidative resistance, which helps provide long-term durability of the implant. 5

For more information, contact,

DePuy Orthopedics
700 Orthopaedic Drive
Warsaw, IN 46582-3900
phone: (800) 366-8143
www.depuyorthopaedics.com

References

  1. "Data on file at DePuy Orthopaedics, Inc.
  2. A. Engh, et al. A randomized prospective evaluation of outcomes after total hip arthroplasty using cross-linked marathon and non—cross-linked Enduron polyethylene liners. J Arthroplasty. 2006; 21 (Suppl. 2).
  3. Kindsfater K, Barrett W, Dowd J, Southworth C, Cassell M. Poster #P077, Midterm survival of the pinnacle Multi—Liner Acetabular Cup in a prospective multi-Center study, 2007. AAOS Annual Meeting.
  4. Data on file at DePuy Orthopaedics, Inc.
  5. Data on file at DePuy Orthopaedics, Inc.

ONCE-YEARLY TREATMENT FOR POSTMENOPAUSAL OSTEOPOROSIS

Reclast® (zoledronic acid) Injection has been approved by the US Food and Drug Administration as a once-yearly medicine for postmenopausal osteoporosis.

Efficacy and safety data from a 3-year Pivotal Fracture Trial showed that Reclast increases bone strength and reduces fractures in area